NSE ScannerHospitals & Diagnostics · Hospital/Nursing Management · NSE: GKSL · data 2026-10-30
Gujarat Kidney & Super Speciality Ltd.
In plain words
Price: 22.2% below its 52-week high of ₹209.8.
Delivery: 55.0% of traded shares were kept for delivery over the last 10 sessions, against 41.7% over the last 60.
Latest results: a net profit of ₹5 cr for the quarter ended Mar 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹101 cr |
| Net profit (last 12 months) | ₹16 cr |
| Sales growth, 3 years (yearly) | — |
| Profit growth, 3 years (yearly) | — |
Latest results in brief (Q4 FY26)
GKSL Q4 FY26 results (consolidated figures, as filed on NSE).
Revenue was ₹30.58 crore, up 31.5% QoQ.
Net profit was ₹5.04 crore, up 71.4% QoQ.
Operating margin was 20.6%.
EPS was ₹0.81, up 55.8% QoQ.
GKSL के Q4 FY26 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹30.58 करोड़; पिछली तिमाही की तुलना में 31.5% की बढ़त।
शुद्ध मुनाफ़ा: ₹5.04 करोड़; पिछली तिमाही की तुलना में 71.4% की बढ़त।
ऑपरेटिंग मार्जिन: 20.6%।
EPS: ₹0.81; पिछली तिमाही की तुलना में 55.8% की बढ़त।
GKSLના Q4 FY26 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹30.58 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 31.5% વધારો.
ચોખ્ખો નફો: ₹5.04 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 71.4% વધારો.
ઓપરેટિંગ માર્જિન: 20.6%.
EPS: ₹0.81; ગયા ક્વાર્ટરની સરખામણીએ 55.8% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
11/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 6/30: Delivery 13.4% over the last 20 sessions vs 37.6% in the 40 before (0.36x); shares delivered per day 1.21x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹15.01 cr in bulk/block deals over 90 days (0 net buying days, 3 net selling days): more sold than bought.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Results
- 26 Oct 26Deal Bulk deal: NEXUS GLOBAL OPPORTUNITIES FUND sold ₹7.81 cr -1.2% next session
- 1 Oct 26Deal Bulk deal: NATVARSINH T CHAVDA sold ₹2.42 cr (net −₹1.52 cr) +6.3% next session
- 22 Sept 26Deal Bulk deal: L7 HITECH PRIVATE LIMITED sold ₹5.68 cr -3.0% next session
- 5 Aug 26Results Q2 FY26 results: net profit ₹2.7 cr +2.6% next session
- 25 Jul 26Results Q4 FY26 results: net profit ₹5 cr -0.6% next session
- 2 May 26Results Q3 FY26 results: net profit ₹2.9 cr +0.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Mar 2026 | ₹31 cr | ₹5 cr | — | 20.6% | 0.81 |
| Sept 2025 | ₹13 cr | ₹3 cr | — | 39.6% | 0.52 |
Common questions
What was Gujarat Kidney & Super Speciality Ltd.'s latest quarterly profit?
Gujarat Kidney & Super Speciality Ltd. reported a net profit of ₹5 cr for the quarter ended Mar 2026, on revenue of ₹31 cr.
Is Gujarat Kidney & Super Speciality Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.12.
What is Gujarat Kidney & Super Speciality Ltd.'s P/E ratio?
About 81.3, based on the last 12 months' earnings and a price of ₹163.31 (data 2026-10-30).
What is the 52-week high and low of Gujarat Kidney & Super Speciality Ltd.?
The 52-week high is ₹209.8 and the 52-week low is ₹98.36.
Similar companies
Indraprastha Medical Corporation Limited (INDRAMEDCO) · KMC Speciality Hospitals (India) Limited (KMCSHIL) · Shalby Ltd. (SHALBY) · GPT Healthcare Limited (GPTHEALTH) · KRM Ayurveda Ltd. (KRMAYURVED)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open GKSL in NSE Scanner →